135 related articles for article (PubMed ID: 36445477)
1. Feasibility of MRI targeted single fraction HDR brachytherapy for localized prostate carcinoma: ProFocAL-study.
Hass P; Fischbach F; Pech M; Gawish A
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5397-5404. PubMed ID: 36445477
[TBL] [Abstract][Full Text] [Related]
2. MRI-Guided Ultrafocal HDR Brachytherapy for Localized Prostate Cancer: Median 4-Year Results of a feasibility study.
Peters M; van Son MJ; Moerland MA; Kerkmeijer LGW; Eppinga WSC; Meijer RP; Lagendijk JJW; Shah TT; Ahmed HU; van der Voort van Zijp JRN
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1045-1053. PubMed ID: 30926575
[TBL] [Abstract][Full Text] [Related]
3. MRI targeted single fraction HDR Brachytherapy for localized Prostate Carcinoma: a feasibility study of focal radiation therapy (ProFocAL).
Fischbach F; Hass P; Schindele D; Genseke P; Geisendorf L; Stehning C; Schostak M; Brunner T; Pech M; Fischbach K
Eur Radiol; 2020 Apr; 30(4):2072-2081. PubMed ID: 31828412
[TBL] [Abstract][Full Text] [Related]
4. The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition.
Pellizzon AC; Salvajoli J; Novaes P; Maia M; Fogaroli R; Gides D; Horriot R
Int J Med Sci; 2008 Jun; 5(3):113-20. PubMed ID: 18566673
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute.
Makino T; Mizokami A; Namiki M
Anticancer Res; 2015 Mar; 35(3):1723-8. PubMed ID: 25750334
[TBL] [Abstract][Full Text] [Related]
6. MRI guided focal HDR brachytherapy for localized prostate cancer: Toxicity, biochemical outcome and quality of life.
Maenhout M; Peters M; Moerland MA; Meijer RP; van den Bosch MAAJ; Frank SJ; Nguyen PL; van Vulpen M; van der Voort van Zyp JRN
Radiother Oncol; 2018 Dec; 129(3):554-560. PubMed ID: 30131183
[TBL] [Abstract][Full Text] [Related]
7. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
[TBL] [Abstract][Full Text] [Related]
8. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.
Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R
Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.
Hsu CC; Hsu H; Pickett B; Crehange G; Hsu IC; Dea R; Weinberg V; Gottschalk AR; Kurhanewicz J; Shinohara K; Roach M
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):370-7. PubMed ID: 22672747
[TBL] [Abstract][Full Text] [Related]
10. Ultra-hypofractionated radiotherapy for low- and intermediate risk prostate cancer: High-dose-rate brachytherapy vs stereotactic ablative radiotherapy.
Tsang YM; Tharmalingam H; Belessiotis-Richards K; Armstrong S; Ostler P; Hughes R; Alonzi R; Hoskin PJ
Radiother Oncol; 2021 May; 158():184-190. PubMed ID: 33639192
[TBL] [Abstract][Full Text] [Related]
11. Dosimetry of local failure with single dose 19 Gy high-dose-rate brachytherapy for prostate cancer.
Armstrong S; Tsang Y; Lowe G; Tharmalingam H; Alonzi R; Ostler P; Hughes R; Hoskin P
Radiother Oncol; 2021 Apr; 157():93-98. PubMed ID: 33493500
[TBL] [Abstract][Full Text] [Related]
12. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
13. Focal high-dose-rate brachytherapy for localized prostate cancer: toxicity and preliminary biochemical results.
Prada PJ; Cardenal J; García Blanco A; Andreescu J; Ferri M; Anchuelo J; Diaz de Cerio I; Sierrasesumaga N; Vázquez A; Pacheco M; Ruiz Arrebola S
Strahlenther Onkol; 2020 Mar; 196(3):222-228. PubMed ID: 31942652
[TBL] [Abstract][Full Text] [Related]
14. Focal Brachytherapy for Localized Prostate Cancer: Midterm Outcomes.
Ta MH; Nunes-Silva I; Barret E; Renard-Penna R; Rozet F; Mombet A; Cathala N; Sanchez-Salas R; Créhange G; Cathelineau X; Cosset JM
Pract Radiat Oncol; 2021; 11(5):e477-e485. PubMed ID: 33422681
[TBL] [Abstract][Full Text] [Related]
15. High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: a 7-year experience.
Aluwini S; van Rooij PH; Kirkels WJ; Jansen PP; Praag JO; Bangma CH; Kolkman-Deurloo IK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1480-5. PubMed ID: 22285661
[TBL] [Abstract][Full Text] [Related]
16. Five-Year Outcomes of a Single-Institution Prospective Trial of 19-Gy Single-Fraction High-Dose-Rate Brachytherapy for Low- and Intermediate-Risk Prostate Cancer.
Siddiqui ZA; Gustafson GS; Ye H; Martinez AA; Mitchell B; Sebastian E; Limbacher A; Krauss DJ
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1038-1044. PubMed ID: 30771408
[TBL] [Abstract][Full Text] [Related]
17. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
18. The effect of catheter displacement and anatomical variations on the dose distribution in MRI-guided focal HDR brachytherapy for prostate cancer.
Maenhout M; van der Voort van Zyp JRN; Borot de Battisti M; Peters M; van Vulpen M; van den Bosch M; Moerland MA
Brachytherapy; 2018; 17(1):68-77. PubMed ID: 28579419
[TBL] [Abstract][Full Text] [Related]
19. [High-dose-rate brachytherapy with external beam radiotherapy for localized or locally advanced prostate cancer].
Matsunobu A; Shioyama Y; Uehara S; Ohga S; Atsumi K; Matsumura T; Sakamoto N; Yoshikawa M; Iguchi A; Honda H
Fukuoka Igaku Zasshi; 2010 Apr; 101(4):75-83. PubMed ID: 20715564
[TBL] [Abstract][Full Text] [Related]
20. Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: toxicity, prostate-specific antigen kinetics, and cancer control.
Mayrata E; Espinosa JM; Büchser D; Casquero F; Suárez F; González A; Minguez P; Pérez JF; Miguel IS; Cacicedo J; Gómez-Iturriaga A
J Contemp Brachytherapy; 2021 Feb; 13(1):12-17. PubMed ID: 34025731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
